Suppr超能文献

荷兰肺癌筛查计划的成本效益分析:基于 NELSON 和 NLST 研究结果的模拟。

Cost-effectiveness analysis of a lung cancer screening program in the netherlands: a simulation based on NELSON and NLST study outcomes.

机构信息

Institute for Diagnostic Accuracy, Groningen, The Netherlands.

Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

出版信息

J Med Econ. 2024 Jan-Dec;27(1):1197-1211. doi: 10.1080/13696998.2024.2404359. Epub 2024 Sep 19.

Abstract

BACKGROUND

In the Netherlands, lung cancer is the leading cause of cancer-related death, accounting for more than 10,000 annual deaths. Lung cancer screening (LCS) studies using low-dose computed tomography (LDCT) have demonstrated that early detection reduces lung cancer mortality. However, no LCS program has been implemented yet in the Netherlands. A national LCS program has the potential to enhance the health outcomes for lung cancer patients in the Netherlands.

OBJECTIVE AND METHODS

This study evaluates the cost-effectiveness of LCS compared to no-screening in the Netherlands, by simulating the screening outcomes based on data from NEderlands-Leuvens Longkanker Screenings ONderzoek (NELSON) and National Lung Screening Trial (NLST). We simulated annual screening up to 74 years of age, using inclusion criteria from the respective studies. A decision tree and Markov model was used to predict the incremental costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICERs) for the screening population. The analysis used a lifetime horizon and a societal perspective.

RESULTS

Compared to no-screening, LCS resulted in an ICER of €5,169 per QALY for the NELSON simulation, and an ICER of €17,119 per QALY for the NLST simulation. The screening costs were highly impactful for the cost-effectiveness. The most influential parameter was the CT scan cost. Cost reduction for CT from €201 to €101 per scan would reduce the ICER to €2,335 using NELSON criteria. Additionally, LCS could prevent 15,115 and 12,611 premature lung cancer deaths, accompanied by 1.66 and 1.31 QALYs gained per lung cancer case for the NELSON and NLST simulations, respectively.

CONCLUSION

LCS was estimated to be cost-effective in the Netherlands for both simulations at a willingness-to-pay threshold of €20,000 per QALY. Using the NELSON criteria, less than €5,500 per QALY had to be spent. Lowering the cost per CT exam would lead to a further reduction of this amount.

摘要

背景

在荷兰,肺癌是癌症相关死亡的主要原因,每年导致超过 10000 人死亡。使用低剂量计算机断层扫描(LDCT)的肺癌筛查(LCS)研究表明,早期发现可降低肺癌死亡率。然而,荷兰尚未实施任何 LCS 计划。国家 LCS 计划有可能改善荷兰肺癌患者的健康结果。

目的和方法

本研究通过基于 NEderlands-Leuvens Longkanker Screenings ONderzoek(NELSON)和 National Lung Screening Trial(NLST)的数据模拟筛查结果,评估与不筛查相比,LCS 在荷兰的成本效益。我们根据各自研究的纳入标准模拟了每年的筛查,直到 74 岁。使用决策树和马尔可夫模型预测筛查人群的增量成本、质量调整生命年(QALYs)和增量成本效益比(ICER)。该分析采用了终生时间范围和社会视角。

结果

与不筛查相比,NELSON 模拟的 LCS 每 QALY 的 ICER 为 5169 欧元,NLST 模拟的 LCS 每 QALY 的 ICER 为 17119 欧元。筛查成本对成本效益影响巨大。最具影响力的参数是 CT 扫描成本。如果将 CT 扫描成本从每次 201 欧元降低到 101 欧元,那么根据 NELSON 标准,ICER 将降低到 2335 欧元。此外,LCS 可以预防 15115 例和 12611 例早期肺癌死亡,同时在 NELSON 和 NLST 模拟中,每例肺癌病例分别增加 1.66 个和 1.31 个 QALYs。

结论

在荷兰,使用 NELSON 标准,LCS 的成本效益估计在两种模拟中都达到了每 QALY 20000 欧元的意愿支付阈值。NELSON 标准下,每 QALY 花费不到 5500 欧元。降低每次 CT 检查的成本将进一步降低这一金额。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验